My perspective is that regulation must balance innovation with rigorous ethical safeguards and a commitment to equity. A multi-tiered approach is necessary. First, strict, transparent guidelines should govern PGD and genetic screening, limiting their clinical use to preventing serious, early-onset medical conditions, as recommended by bodies like the ASHG and ESHG. Second, policy must aggressively address cost and access. For treatments, models like value-based pricing and compulsory licensing could be explored, as the current profit-driven model (evident in the cystic fibrosis drug’s $300,000/year price tag) is ethically unsustainable. Public health systems must negotiate forcefully, and international frameworks should ensure life-saving drugs are not the sole province of rich nations. Ultimately, the goal of genetic medicine should be to alleviate human suffering, not to create new forms of inequality or to commodify human life.